

2022 #32

September 9, 2022

**INSIDE:**

Phase I In-human Trial of Potential RBC Substitute Reported.....2

RESEARCH IN BRIEF ....3

Member Employee Retention & Turnover Survey Results Are Available.....4

Celebrate International Donor Recruitment Professionals Day on September 15<sup>th</sup>.....4

ABC Webinar: Navigating HIPAA and PHI in Community Blood Donor Centers.....4

ABC Launches 2022 Benchmarking Survey for Service Fees .....4

REGULATORY NEWS....5

PEOPLE .....5

IN MEMORIAM .....6

GLOBAL NEWS .....7

COMPANY NEWS .....7

CALENDAR.....8

EQUIPMENT AVAILABLE .....9

POSITIONS.....9

## Health Canada Authorizes Héma-Québec Submission for Move to Individual Risk-based Donor Screening Criteria

Health Canada, the country's regulatory authority, [announced](#) this week that it has "authorized a submission from Héma-Québec to implement a more inclusive approach to blood donor screening." According to a news release from the agency, the new approach "eliminates the current three-month blanket donor deferral period for all [sexually active gay and bisexual men], and instead screens all donors, regardless of gender or sexuality, for high-risk sexual behavi[o]r." Nathalie Fagnan, CPA, CA, president and chief executive officer of Héma-Québec, [stated](#) in a news release, "[t]his new, more inclusive approach will place Héma-Québec among the leaders on the international stage in its field of activity. A more inclusive approach that respects the safety of the products transfused to those who need them is also in line with our commitments to social responsibility. It is consistent with the actions we have taken since 2013, with the approval of Health Canada, for [sexually active gay and bisexual men]. Making this humanitarian gesture even more inclusive and accessible to a greater number of people, regardless of their gender or sexual orientation, is an important step forward."

According to Health Canada, "Héma-Québec has indicated it expects to implement the new donor screening approach in early December. Under the new approach, Héma-Québec will introduce a sexual behavi[o]r-based donor-screening questionnaire that will apply to all blood and plasma donors. The new questions are the same as those [authorized](#) in April 2022 for Canadian Blood Services for use in the rest of Canada."

Héma-Québec explained in their news release that "[t]he use of a gender-neutral questionnaire will have an impact on everyone who wants to donate. Regular donors will see some changes to the mandatory questionnaire they must complete before each donation. These new questions will ask about sexual behavi[o]r and pregnancy history. Those who report having a new partner within the last three months, or multiple partners, will be asked additional questions... The gender-neutral questionnaire will be rolled out in two stages in Quebec. The measure will be applied to plasma donations as of October 2<sup>nd</sup>, following an initial fav[o]rable decision by Health Canada last March. Since then, our teams have been working on the adjustments to be made to operations at the collection sites and in the computer systems, as well as training the teams."

The latest authorization by Health Canada "builds on Canada's progress toward a more inclusive blood donation system nationwide. Health Canada has authorized several changes to the donor deferral period for [sexually active gay and bisexual

(continued on page 2)



## Health Canada Authorizes Héma-Québec Submission (continued from page 1)

men] over the last decade. This year, in March 2022, Health Canada approved a [submission](#) from Héma-Québec to move to sexual-behavi[o]r based screening for all source plasma donors...These changes build on a previous reduction in the donor deferral period from a lifetime, to [five](#) years, to [one](#) year, to [three](#) months. These evidence-based reductions to the original lifetime restriction have not resulted in any increase in HIV-positive blood donations.”

(Sources: Health Canada [News Release](#), 9/6/22; Héma-Québec [News Release](#), 9/6/22) 💧

## **Phase I In-human Trial of Potential RBC Substitute Reported**

A research [letter](#) authored by investigators in Japan has been published in *Blood Advances* reporting on the first-in-human phase I clinical trial of hemoglobin-vesicles (HbVs) developed as a transfusion alternative. The researchers explained that hemoglobin-based oxygen carriers (HBOCs) “can be useful because they are pathogen-free, blood-type-free, and capable of long-term preservation.” HBOCs are chemical entities designed to provide an alternative to red blood cell transfusion in a variety of clinical settings.

For this trial, the authors have developed and used an alternative to first-generation HBOCs. These have been known to “entail statistically higher risks of myocardial infarction and death in the clinical trials [presumably] related to their small molecular sizes, high intrinsic affinities to nitric oxide (NO), and their acellular structure, which collectively cause extravasation, vasoconstriction, hypertension, and oxidative lesion.”

The HbVs developed by the authors “are cellular-structured HBOCs encapsulating a purified and concentrated Hb solution in PEGylated phospholipid vesicles (liposomes; mean particle diameter, 225–285 nm), shielding all the toxic effects of molecular hemoglobin by means of a lipid bilayer membrane and by mimicking erythrocytes.” They noted that the efficacy of HbVs “as a resuscitative fluid has been studied extensively in animal models” leading to the first in-human open-label, single intravenous injection trial “from 2020 to assess HbV safety and pharmacokinetics in healthy male adult volunteers.”

The letter explained that the trial enrolled “healthy male volunteers, aged 20–50 years old” and included dose-escalation as three cohorts received 10, 50, 100 mL doses. “The HbV final product was suspended in saline to give hemoglobin content of 8.5–11.6 g/dL. The HbV suspension was administered at a rate of 1 mL/min in cohort #1. In cohorts #2 and #3, the HbV suspension was administered at 1 mL/min for 10 min, followed by 2.5 mL/min...Blood chemistry tests, hematology-related laboratory tests, and urinalyses were performed before and after administration.”

Multiple adverse events (AEs) were observed which the authors described as “tolerable and spontaneously resolved” including liposome-induced infusion reactions and elevated body temperatures. However, the authors stated that, “[e]xcept for body temperature, no clinically significant change was found in vital signs, including systemic systolic blood pressure. This finding suggests that, compared with the first-generation of HBOCs, HbVs have less potential, if any, for raising risks of myocardial infarction...Pharmacokinetic analysis results revealed that HbVs circulate in the bloodstream with a half-life of approximately 8 h...Results strongly suggest that HbVs can function as oxygen carriers for several hours in the bloodstream of hemorrhagic-shock patients until a transfusion of packed red blood cells can be prepared.”

The letter concludes with the investigators reporting that “[a]ll deviated laboratory test results recovered

(continued on page 3)

### RBC Substitute In-Human Trial (continued from page 2)

without clinical sign or symptom associated with them... We plan to conduct dose escalation studies starting from 100 mL, with premedication using a larger number of subjects in a Phase II trial.”

**Citation:** Azuma, H., Amana, T., Kamiyama, N., *et al.* “[First-in-human phase 1 trial of artificial red blood cells and hemoglobin vesicles developed as a transfusion alternative.](#)” *Blood Advances*. 2022. ♦

## RESEARCH IN BRIEF

**Red Blood Cell Volume Is Associated with Mortality in Neonatal Extracorporeal Membrane Oxygenation (ECMO).** A study published in *Transfusion* “sought to identify potential associations between transfused blood products and mortality in neonates receiving extracorporeal membrane oxygenation (ECMO) support for primary respiratory failure... This retrospective, single center cohort study [included] neonates (<28 days) who received ECMO support in the neonatal intensive care unit (NICU) for respiratory indications between January 1, 2002 and December 31, 2020 (n = 248).” The authors explained that the “analysis plan [used] a single composite mortality risk score that is specific for neonatal respiratory failure patients receiving ECMO (<http://www.Neo-RESCUERS.com>)... The mean age at ECMO initiation was 2.25 ± 1.61 days. Overall survival to ECMO discontinuation was 92.3 percent and survival to discharge was 87.1 percent... For the entire cohort, the mean Neo-RESCUERS score was -1.5, which correlates with a 20 percent mortality risk... An average of 40 ml/kg/day of total transfused blood product was given during ECMO, with platelets accounting for the largest blood product component in each group (56 percent) while leukoreduced packed red blood cells (PRBC’s) account[ed] for about 27 percent of the total product transfused.” The authors noted that “[t]hose who did not survive received higher volumes of every product and total blood product volume when compared to survivors (p <.0001). PRBC, platelet, plasma, and total transfused volume were significantly correlated with ‘Death on ECMO’ but only PRBC volume was significantly correlated with ‘Death after ECMO.’” The study found that “[a] significant interaction with Neo-RESCUERS score was observed in the simple model for ‘Death on ECMO’ but not ‘Death after ECMO’... The final adjusted models demonstrated a significant correlation with PRBC HR 1.136 (1.041–1.240), p=.0043, but not platelet or plasma volume for ‘Death on ECMO.’” The authors concluded “that transfused PRBC volume, but not platelets or plasma volume, are independently associated with a higher mortality risk in neonatal ECMO for respiratory failure.” They added that the “study supports the overall trend of lowering transfusion thresholds while on ECMO to avoid increasing the mortality risk.”

**Citation:** Gancar, J.L., Shields, M.C., Wise, L., Waller, J.L., Stansfield, B.K. [Red blood cell volume, but not platelet or plasma volume is associated with mortality in neonatal ECMO.](#) *Transfusion*. 2022.

Contributed by Richard Gammon, MD, Medical Director at OneBlood ♦

The ABC Newsletter (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2022 by America’s Blood Centers. Reproduction of the ABC Newsletter is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

### America’s Blood Centers

Chief Executive Officer: Kate Fry  
Chief Medical Officer: Rita Reik  
Editor: Mack Benton  
Subscriptions Manager: Leslie Maundy  
**Annual Subscription Rate: \$390**

Send subscription queries to  
[memberservices@americasblood.org](mailto:memberservices@americasblood.org)  
America’s Blood Centers  
1717 K St. NW, Suite 900, Washington, DC 20006  
Phone: (202) 393-5725  
Send news tips to [newsletter@americasblood.org](mailto:newsletter@americasblood.org).



**America's Blood Centers**  
It's About *Life*.

## INSIDE ABC

*The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.*

### **Member Employee Retention & Turnover Survey Results Are Available**

Results of the America's Blood Centers (ABC) Member Employee Retention & Turnover Survey are available to ABC members in MCN 22-077. Please contact [us](#) to receive a copy. This benchmarking survey provides ABC members with insights into blood center experiences, the impact of human resources- (HR) related issues to blood center operations, and policy solutions centers have implemented to promote employee retention. In addition to the aggregate data from 2021, the report includes turnover rates for the first five months of 2022, providing a quick check-in on the progress centers are making this year. Results of the survey will also be presented in the upcoming [ADRP 2022 Master Class](#) on September 28<sup>th</sup>. [Registration](#) is open.

(Source: MCN 22-077, 9/2/22)

### **Celebrate International Donor Recruitment Professionals Day on September 15<sup>th</sup>**

ADRP, an International division of ABC is encouraging individuals to take part in [International Donor Recruitment Professionals Day](#) on September 15<sup>th</sup>. Blood centers have the opportunity to recognize their colleagues who work in recruitment using the hashtags #SavingLives, #DonorRecruitmentProfessionals, #TakeTheCallToSaveALife on social media. Also, please share your celebrations on ADRP's [CollABOrate](#).

### **ABC Webinar: Navigating HIPAA and PHI in Community Blood Donor Centers**

ABC will host a webinar on September 13<sup>th</sup> titled "Navigating HIPAA and PHI in Community Blood Donor Centers." The webinar will take place from 3-4 pm EDT and will feature Roxanne Tata, MT(ASCP) SBB, CQA (ASQ), vice president of Regulatory Affairs and Corporate Quality Services at Vitalant. She will share her expertise in differentiating and protecting HIPAA and PHI (Protected Health Information) at community blood donor centers as well as the impact of electronic devices use on securing the information. P.A.C.E. credits will be available as well as a webinar recording. This is the first in a two-part series as Richard Dunn, CISM, ISACA, manager of Security and Resilience at Gulf Coast Regional Blood Center will present on an ABC webinar on September 20<sup>th</sup> from 3-4 pm EDT on: "Navigating Cybersecurity in Community Blood Centers." More information on this webinar will be coming soon. Additional details including a link to join the first webinar are available to ABC members in MCN 22-075. Contact [us](#) to receive a copy of the MCN.

(Source: MCN 22-075, 8/30/22)

### **ABC Launches 2022 Benchmarking Survey for Service Fees**

ABC recently launched its annual benchmarking survey for member service fees. All ABC member blood centers are encouraged to participate. The results of this survey are an important part of ABC's advocacy efforts for better CMS reimbursements for blood products. The data from the report will be aggregated and no individual member data will be shown. Members are asked to complete the survey by September 23<sup>rd</sup>.

(continued on page 5)

INSIDE ABC (continued from page 4)

A link to the survey and a PDF version are available to ABC members in MCN 22-073. Please [contact](#) ABC Director of Regulatory Affairs Jill Mastin with any questions.

(Source: MCN 22-073, 8/24/22) ♦

## REGULATORY NEWS

The Association for the Advancement of Blood & Biotherapies (AABB) published [Association Bulletin #22-03](#) which provides “Updated Recommendations on Donor Deferral for Use of Antiretroviral Medications for HIV Prevention and Treatment including Long-Acting Injectable PrEP and the Impact on Blood Safety.” According to announcement from AABB, the Bulletin “was developed by AABB’s Transfusion Transmitted Diseases (TTD) Committee and the Donor History Task Force (DHTF), including representatives from the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). [It] provides recommendations to update and replace the donor eligibility recommendations in AB #20-04 The Impact on Blood Safety of Effective Antiretroviral Medications for HIV Prevention and Treatment (now [obsolete](#)). The Bulletin reflects new information regarding the impact of donor use of long-acting, injectable cabotegravir (trade name Apretude) as pre-exposure prophylaxis (PrEP) [approved](#) by FDA in late December 2021.”

(Source: AABB Announcement, 9/8/22) ♦

## PEOPLE



Versiti has announced that **Barbara J. Bryant, MD, FCAP, FASCP** will become executive vice president and chief medical officer in November. Dr. Bryant previously held the role of vice president of Transfusion Medicine at the organization. She currently serves as the chief of the Department of Transfusion Medicine and the Center of Cellular Engineering at the National Institutes of Health (NIH) Clinical Center. While at NIH, she was a member of the U.S. Department of Health and Human Services (HHS) Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) and the Public Health Service Blood, Organ, and Tissue Senior Executive Council. During her career, Dr. Bryant has also served on the U.S. Food and Drug Administration (FDA) Blood Products Advisory Committee (BPAC), the board of directors of the Association for the Advancement of Blood & Biotherapies, and president of the South Central Association of Blood Banks. According to the Versiti announcement, she “received her undergraduate degree from the University of New Orleans and LSU Medical Center. [Dr. Bryant] was a blood bank medical technologist and specialist in blood banking for 17 years before attending medical school. [She] earned her medical degree from UTMB where she completed a residency in Pathology. She did her fellowship training in Transfusion Medicine/Blood Banking at the NIH.”

(Source: Versiti Announcement, 9/9/22)

(continued on page 6)





PEOPLE (continued from page 5)

**Marion Lanteri, PhD** has been [named](#) vice president of Scientific Affairs at Creative Testing Solutions (CTS). According to a company news release, she will “lead all CTS’s scientific activities, clinical trials, research, data collection, analysis, and publication” in this role. “Blood transfusions and blood derivatives are integral to patient’s healthcare,” said Dr. Lanteri in the news release. “Blood screening plays a critical role in blood safety, of which blood donor research is a key component of this process. I am honored to continue to serve as a leader in this important endeavor, something I’ve strived to do over my nearly 20-year career.” Dr. Lanteri’s career includes 12 years at the Vitalant Research Institute in San Francisco, Calif. where she began as a post-doctoral student “researching immunology and specializing in West Nile, dengue, and Zika virus research and in pathogen inactivation.” She received a doctorate in Molecular Biology and Virology at the University of Nice Sophia-Antipolis in France where she specifically studied HIV. Dr. Lanteri is “a member of the American Society for Virology, the Association for the Advancement of Blood and Biotherapies, and the International Society of Blood Transfusion. [She] has authored or co-authored over 60 peer-reviewed publications.”



(Source: CTS [News Release](#), 9/8/22)



**Christopher Hillyer, MD**, president and chief executive officer at New York Blood Center Enterprises, was recently [honored](#) by *Crain’s New York Business* as one their 2022 “Notable Health Care Leaders.” He is one of 86 individuals to receive the distinction this year as the publication recognizes those “who have helped New Yorkers and people worldwide lead healthier lives through their dedication, innovation, and sacrifice. [Individuals] making [the] “Notable Health Care Leaders” list come from hospitals, government agencies, tech startups, and related fields. The honorees are notable for their consummate leadership, pioneering accomplishments, and ability to adjust to crises. Moreover, all of them have demonstrated a commitment to mentoring.” Among Dr. Hillyer’s recent

accomplishments are:

- “[n]avigating [the] organization through significant challenges, including the recent pandemic and spearheading the nation’s efforts to supply convalescent plasma to COVID patients in need while facilitating COVID therapies and vaccine clinical trials;
- [c]hampioning New York Blood Center Enterprises’ longstanding commitment to sickle cell patients, including meeting transfusion needs and developing new treatments for sickle cell complications, as well as novel strategies to help cure the disease through stem cell transplantation and gene therapy;
- [w]orking to secure the New York City Council’s approval for the rezoning of Center East, forging a path to create the Center East Life Sciences Hub that will support innovation and the organization’s mission to provide blood and stem cell products to the community; [and]
- [c]reating New York Blood Center Ventures, the first and only venture fund solely focused on fostering innovation in blood and blood disease-related medicines and technologies.”

(Source: New York Blood Center Enterprises [Announcement](#), 8/24/22) 💧

## IN MEMORIAM

**Charles Herman Drummond** [passed](#) away on August 27<sup>th</sup> at the age of 81. According to an obituary published by *The Virginian-Pilot*, “[he] Born in Newport News, V.A. Mr. Drummond was a retired chief executive officer of Tacoma Community Blood Center in Washington state. During his career he managed

(continued on page 7)



## IN MEMORIAM (continued from page 6)

blood centers across the country for over 40 years. His passions were his family, gardening, and wood working. He was preceded in death by his parents Herman and Sara Drummond. He is survived by his wife Debbie, his daughter Rachel Brannen and husband Stephen; his two sons John Drummond and his wife Patricia and Mike Drummond and his wife Krista; his sister Martha Drummond-Dale and husband Les. He has been blessed with nine grandchildren and three nephews. A celebration of life was held on September 2<sup>nd</sup>...[The] family requests in lieu of flowers, memorials be made to the church or charity of your choice.”

(Source: Charles Drummond [Obituary](#), 8/30/22) 💧

## GLOBAL NEWS

**Canadian Blood Services and Grifols announced a [partnership](#) this week aimed to “accelerate” the self-sufficiency of immunoglobulins (Ig) for Canada.** According to a news release, the agreement will “ensure Canadian plasma is processed into Ig medicines on Canadian soil for the exclusive needs of the thousands of patients in the country who critically depend on these lifesaving therapies. Canada has a high Ig usage rate and currently needs to import as much as 85 percent of its Ig, with demand growing an average of 5-8 percent annually. The collaboration [will combine with] the work already being done by Canadian Blood Services to accelerate Canada’s Ig self-sufficiency rate from 15 percent to 50 percent in the shortest time possible. Under the agreement, Grifols will work with Canadian Blood Services to steadily increase sourcing of the Canadian plasma necessary so that volumes eventually reach 2.4 million grams of Ig medicines annually by 2026.”

(Source: Grifols and Canadian Blood Services [News Release](#), 9/7/22) 💧

## COMPANY NEWS

**Haemonetics Corporation** announced a [partnership](#) with **Epic** to “offer” Haemonetics’ transfusion management system to hospitals within Epic’s global network. “[Our transfusion management system] provides complete visibility of patients and blood products for blood banks across the care continuum,” said Haemonetics President of Global Hospital Stew Strong in a news release. “As staffing and blood supply shortages persist, we look forward to helping more hospitals within Epic’s network leverage [our system] for greater transfusion safety and efficiency.”

(Source: Haemonetics [News Release](#), 8/29/22) 💧



**Fresenius Kabi and the Association for the Advancement of Blood & Biotherapies (AABB) [celebrated](#) the 17<sup>th</sup> annual Blood Collectors Week from September 4<sup>th</sup>-10<sup>th</sup>.** According to a news release, the week-long celebration honor[s] blood collectors “for the lifesaving work they do each day as the essential connection between blood donors and the patients who count on blood for a multitude of medical conditions.” The organizations encouraged “[t]hose celebrating [to] show their support on social media by sharing photos using the hashtags #BloodCollectorsWeek and #SavingLives. To learn more about blood donation, find a local blood collection site, or download resources for your Blood Collectors Week celebration, visit <https://bloodcollectors.org> and follow the [@bloodcollectors](#) Twitter account.

(Source: Fresenius Kabi and AABB [News Release](#), 9/4/22) 💧

## CALENDAR

**Note to subscribers:** Submissions for a free listing in this calendar (published weekly) are welcome. Send information to [newsletter@americasblood.org](mailto:newsletter@americasblood.org). (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)

### 2022

Sept. 19-22. **American Association of Tissue Banks Annual Meeting, San Antonio, Texas.** More information available [here](#).

Sept. 20-22. **2022 Center for Biologics Evaluation and Research (CBER) Science Symposium (Virtual).** Registration is [open](#). More information available [here](#).

Sept. 21-22. **28<sup>th</sup> IPFA/ Paul-Ehrlich-Institut[e] (PEI) International Workshop on Surveillance and Screening of Blood-borne Pathogens, Porto, Portugal.** Registration is [open](#). More information available [here](#).

Sept. 28-29. **2022 ADRP Master Class (Virtual).** Registration is [open](#).

Sept. 28-29. **BEST Meeting LXIV, Cocoa Beach, Fla.** More information available [here](#).

Oct. 1-4. **Association for the Advancement of Blood & Biotherapies Annual Meeting, Orlando, Fla.** Registration is [open](#). More information available [here](#).

Oct. 4-5. **U.S. Department of Health and Human Services (HHS) Tick-Borne Disease Working Group Meeting (Virtual).** More information available [here](#).

Oct. 25. **(HHS) Tick-Borne Disease Working Group Meeting (Virtual).** More information available [here](#).

Nov. 15-16. **The Biomedical Advanced Research and Development Authority (BARDA) Industry Day (Virtual).** More details available [here](#).

Dec. 7. **(HHS) Tick-Borne Disease Working Group Meeting (Virtual).** More information available [here](#).

### 2023

Mar. 6-8. **ABC Annual Meeting, Washington, D.C.** More information coming soon.

May 9-11. **2023 ADRP Conference, Charlotte, N.C.** More information coming soon. 💡

### Upcoming ABC Webinars – Don’t Miss Out!

- **ABC HIPAA & Privacy in Blood Banking Webinar** – September 13 from 3-4 PM EDT. More information coming soon.
- **ABC Cybersecurity Threats & Mitigation for Blood Centers Webinar** – September 20 from 3-4 PM EDT. More information coming soon.
- **ADRP vCJD Implementation – Soup to Nuts Webinar** – October 12 from 1-2 PM EDT. More information coming soon.



## EQUIPMENT AVAILABLE

**For Sale.** New and Unused CompoMat G5 Units. The Blood Bank of Alaska has three new and unused CompoMat G5 Units for sale. These units have not been validated or used. If interested, please contact Bryan Baynard at [bbaynard@bbak.org](mailto:bbaynard@bbak.org) or (907) 222-5664.

## CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: [newsletter@americasblood.org](mailto:newsletter@americasblood.org)

## POSITIONS

**Executive Director, Blood Operations (Shreveport, LA).** LifeShare Blood Center is seeking an experienced operations manager as our **Executive Director** to provide leadership and strategically direct all blood operations and donor support operations, in fulfillment of the Company's strategic goals and business plan. Reporting to the Chief Operating Officer, the Executive Director will strategically lead LifeShare's community outreach, branding, marketing, and blood donor recruitment efforts; provide high-level direction of blood collection operations; and provide oversight of hospital services and component manufacturing to meet customer needs. **Please join us in our important mission to connect blood donors and the lives they impact!** LifeShare offers a competitive beginning salary, commensurate with experience and a generous benefits package, including employer-paid medical, life and disability insurance; employer base retirement and matching contributions to the 401(k) savings plan, paid time off bank, and employee wellness program. Please visit our [Careers Page](#) to apply.

**Director, Regulatory Affairs and Public Policy.** America's Blood Centers (ABC), North America's largest network of community-based, independent blood programs, is seeking a **Director, Regulatory Affairs and Public Policy**. The position is a key role for ABC and will provide the successful candidate an opportunity to lead a strategic area of work while benefitting from the flexibility of a fully remote office environment. The Director, Regulatory Affairs and Public Policy will assist in the development, implementation, execution, and advancement of the ABC Advocacy Agenda before federal agencies and other stakeholders. Responsibilities: Analyze, evaluate, communicate, and track the impact of new regulatory and science, medical, technical (SMT) developments on ABC member centers, including working with members and staff in the development of policy positions, public statements, and comment letters and responses to information requests from federal agencies. Build strategic relationships as a liaison with appropriate staff at FDA and other federal agencies as necessary (including HHS, OSHA, DOL, NCR, CDC, DOD, and others), and non-governmental industry partners. Serve as an ABC representative and spokesperson to industry coalitions. Conduct routine operational and ad hoc member surveys that support the ABC Advocacy Agenda.

Work includes the creation of survey forms and protocols, analysis of data, and preparation and dissemination of reports. Educational Requirements: Bachelor's required. Experience, Knowledge, Skills and Abilities: Seven plus years of experience with public policy and regulatory affairs, preferably with FDA. Click [here](#) to view the full job description. Interested applicants should send a cover letter and resume to [careers@americasblood.org](mailto:careers@americasblood.org).

**Territory Representative.** Dedicated team members are the vital link between volunteer blood donors and hospital patients who rely on lifesaving blood transfusions and work diligently to ensure their friends, families, hospitals have access to a strong blood supply. LifeServe Blood Center's foundation is based on local blood donors supporting the needs of their local hospitals. F/T employees are eligible for medical, dental, vision, critical illness, supplemental insurance, short/long-term disability, life insurance, 403b and four weeks of PTO. Primary Responsibilities: Recruit, direct, and train volunteers to organize drives. Establish sales strategies to grow donor base. Coordinate resources associated with blood drives to ensure success. Conduct speaking engagements and participates in workshops/presentations/health fairs. Proactively works to meet individual monthly goals while also working collaboratively with the team to ensure weekly, monthly, and yearly blood goals are met. Follow all guidelines for completion of recruiting materials and scheduling mobile drives. Maintaining accurate records to provide tracking and statistical data on account performance. Education and/or Experience: Bachelor's degree in business, marketing, advertising, or communications is preferred. H.S. diploma and five plus years of recruitment, sales, marketing, volunteer management required. Interested applicants should apply at: [Join Our Team - LifeServe Blood Center](#).

**Immunohematology Technician.** LifeServe Blood Center is currently looking for a certified Medical Technician with the desire to provide exceptional customer service to our hospital partners and the patients they serve in IA,

(continued on page 10)

## POSITIONS (continued from page 9)

NE, and SD. Work in our state-of-the-art laboratory and will handle basic blood banking and complex antibody identification. F/T employees are eligible for a full benefit package including medical, dental, vision, critical illness, supplemental insurance, short/long term disability, life, company matching 403b, and four weeks of PTO. Shift differential is available for hours worked after 6:00 PM. Primary Responsibilities: Accepts, verifies, processes, and tests samples according to policies. Performs and interprets various testing procedures, including immunohematology, on donor and patient blood products. Performs quality control, maintenance, and calibration. Utilizes computers to obtain necessary data and to record test results. Monitoring testing processes to identify errors or problems leading to errors and takes effective and preventive corrective actions when indicated. Mentors and trains other laboratory team members and students. Education and Experience: MT/MLS or MLT from ASCP or equivalent. Bachelor's degree in medical technology or chemical, physical or biological science or related scientific field from an accredited college or university or an equivalent combination of education, certification, training and or experience. Meet current CLIA or ABB requirements for testing personnel. Interested applicants should apply at: [Join Our Team - LifeServe Blood Center](#).

**Manager of Technical Services.** The Blood Connection is looking for a Manager of Technical Services in Morrisville, NC. This is a new role that will be responsible for supervising and managing the daily operations of the technical departments: Hospital Services, Component Manufacturing/Biologics Processing and Immunohematology Reference Laboratory. We offer a generous benefits package including a great 401k match, tuition reimbursement, yearly increases, company bonus, cell phone stipend, and 30 days PTO. Join our team and help make an impact in your community today! Relocation assistance offered. Click [here](#) to apply.

**Director of Hospital Services and Manufacturing.** Blood Bank of Alaska (BBAK) is seeking a director to oversee our Hospital Services and Manufacturing Department in Anchorage, AK. This position is responsible for ensuring our manufacturing and distribution areas are operating in compliance with applicable government regulations, and accrediting agency standards. Also ensuring there is a dedicated focus on the production and distribution of quality products while providing the highest level of customer service. The Director will participate as a member of the blood bank's management team in planning, program formulation, and decision making for the functions and technical support of the manufacturing and distribution of blood products. The incumbent for this role must possess excellent conceptual, communication and analytical skills. Must understand general workflow processes and equipment used in a

medical facility. The right candidate will have a bachelor's degree in a relevant field (required) and five years of supervisory experience in a highly regulated, fast-paced, and compliance-driven environment (preferred). We are committed to providing our employees with the support they need. At BBAK we offer an attractive benefit package that includes: Medical, Dental, Vision, Life Insurance, Health Savings Plan, Paid Time Off, 401 K with matching and Short Term & Long-Term Disability coverage. If you meet the above qualifications, please apply by sending your resume to: [mcannon@bbak.org](mailto:mcannon@bbak.org). For more information about the Blood Bank of Alaska, please visit our website at <https://www.bloodbankofalaska.org>.

**Medical Director (Gulf Coast Regional Blood Center).** Reporting to the Chief Medical Officer, this individual will assist in providing oversight of operational and implementation expertise across multiple areas of a large community blood center. Areas of responsibility include medical oversight of selection and care of donors, collection, processing, and testing of blood, and disease notification. In addition, this individual will provide guidance for The Blood Center's transfusion service activities and cellular therapy programs, as well as serving as a liaison with medical staff in the community to address transfusion concerns and assure the appropriate utilization of blood products. Requirements: Doctor of Medicine or Doctor of Osteopathy degree from an accredited university with at least four years of combined education and experience in blood banking/transfusion medicine or related field. Board certified or board-eligible in Pathology, Hematology, or related field. Specialty training and/or certification in Blood Banking, Hematology, or a similar related field is highly desirable. Eligible for medical license in the state of Texas. Applicants with additional medical or management experience in apheresis related to cellular therapy and transplant are strongly encouraged to apply. Click [here](#) to apply.

**Divisional Director.** The Blood Connection, formerly Carolina-Georgia Blood Center, is expanding our operations into Augusta, Georgia! We are one of the fastest growing blood centers in the country and we are looking to hire a Divisional Director who will be responsible for our day-to-day operations and help direct our expansion of services into this new territory. The ideal candidate is a results-focused self-starter with progressive leadership experience and the drive to help fulfill the needs of our community partners. We offer a generous benefits package including a great 401k match, tuition reimbursement, yearly increases, company bonus, cell phone stipend, and 30 days PTO. Join our team and help make an impact in your community today! Click [here](#) to apply.

**Donor Testing Laboratory Director.** LifeSouth Community Blood Centers and The National Blood Testing

(continued on page 11)

POSITIONS (continued from page 10)

Cooperative (NBTC) are currently seeking a skilled individual for the Donor Testing Laboratory Director position in the NBTC owned Donor Testing Laboratory in **Stone Mountain, GA**. This position is responsible for the strategic planning, development, organization, coordination, management, and daily oversight of all activities associated with a blood testing laboratory. This position will also ensure the laboratory performs in accordance with all regulatory requirements and will possess the oversight and responsibility of all standard operating procedures (SOPs) within the lab. Must have bachelor's degree in: chemical, physical, biological, clinical laboratory science, or medical technology. Scientific and technical knowledge from current sources, such as the AABB Standards and relevant guidances related to FDA, CLIA, and CMS, both state and federal. Minimum of four years of management/supervisory experience required; Equivalent combination of demonstrated work experience and education may be considered. Starting salary range is \$135,000 - \$150,000 annually. Click [here](#) to apply. ●